On November 10, 10x Genomics, Inc. fell 5.1% in Regular Trading, trading at $62.6 per share, with turnover of $6.8689 million.
The move followed continued pressure from post-earnings analyst target reductions, even after the company reported results above expectations and raised its full-year revenue outlook.
In its latest quarterly report, 10x Genomics, Inc. posted a Q3 loss of $0.15 per share, better than estimates for a $0.25 to $0.27 loss, while revenue of $150.667 million exceeded expectations near $147.9 million to $148.0 million. The company also lifted full-year revenue guidance to $625 million-$635 million from $610 million-$630 million, above the consensus estimate of $620.8 million. However, several firms subsequently lowered price targets, including UBS to $61 from $90, Barclays to $70 from $110, and BofA to $65 from $80, reflecting continued caution on growth durability and valuation.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments